Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Schreiner MediPharm, Applied DNA Offer Forensic Authentication Feature | Contract Pharma

What are you searching for?

Sign in

Schreiner MediPharm, Applied DNA Offer Forensic Authentication Feature

SigNature is based on DNA markers which are deemed to be impossible to counterfeit and recognized as forensic authentication evidence in courts of law

By: Cassandra Gervolino

Schreiner MediPharm now offers a new forensic authentication feature for pharmaceutical labels in cooperation with Applied DNA Sciences. SigNature DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect products against counterfeiting, and patients against potential health risks. DNA markers are deemed to be impossible to counterfeit and recognized as forensic authentication evidence in courts of law. 

“The integration of SigNature® DNA in combination with Beacon® in our functional pharma labels will set a new security standard in the pharmaceutical industry,” summarizes Nadine Lampka, Product Manager Pharma-Security at Schreiner MediPharm. “DNA-Secure is extremely robust, flexible to integrate and allows both a quick in-field test and an ultimate forensic proof in the lab. It provides excellent value for the investment, and complements our portfolio of integrated authentication features on the high-security end.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters